Developing non-traditional antibiotics promises novel strategies to combat multidrug-resistant organisms but would they work? Are they feasible to develop?

Topics discussed: 
 • The notion of non-traditional antibiotics as potential therapeutics against MDR organisms 
 • Increasing our understanding on the clinical efficacy of non-traditional antibiotics 
 • Regulatory pathways for approval of such compounds


Guest: Dr. John Rex, Chief Medical Officer, F2G Ltd. | Editor-in-Chief, AMR.solutions

Visit https://aac.asm.org to browse issues and/or submit a manuscript.